tbuckley/cabot-search huggingface dataset:
Effect of spiritual care on the quality of life in patients who underwent intracranial hemorrhage surgery: a randomized controlled trial
Authors: Rasoul Goli, Navid Faraji, Himan Maroofi, Amireh Hassanpour
Journal: International Journal of Surgery (2023)

Introduction: One of the most important complications of stroke after intracranial hemorrhage surgery is impaired quality of life. This study was conducted to determine the impact of spiritual care on the quality of life of stroke patients. Methods: This single-blind clinical trial with a pretest and posttest design was conducted on 100 stroke patients. Participants were recruited and randomly assigned to a control group and an intervention group. The Stroke-Specific Quality of Life Scale (SS -QoL) was used to assess the quality of life of stroke patients. The intervention group received four sessions of spiritual care. Results: The independent t test showed no significant difference between the 2 groups in the mean quality of life score (t=−0.120, P =0.281) and its dimensions before the intervention. However, after the intervention, the results showed a significant difference between the two groups in terms of the mean quality of life score (t=1.984, P &lt;0.001) and its dimensions. In addition, the results of the paired t test showed that in the intervention group, the mean score of quality of life (t=5.161, P &lt;0.001) and its dimensions were significantly different before and after the intervention. Furthermore, the results showed that before and after the intervention in the control group, the mean score of quality of life (t=1.109, P =0.614) and its dimensions were not significantly different. Conclusion: Based on our results, we strongly recommend the use of spiritual care as a holistic care and complementary method to improve the symptoms and quality of life of stroke patients.
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Authors: Patrick M. Grierson, Rama Suresh, Benjamin Tan, Katrina S. Pedersen, Manik Amin, Haeseong Park, Nikolaos A. Trikalinos, Jingxia Liu, Nicholas Boice, Amberly Brown, Sapana Bansod, Andrea Wang-Gillam, Kian-Huat Lim
Journal: Clinical Cancer Research (2023)

Abstract Purpose: Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models. Patients and Methods: We conducted a pilot study to evaluate the safety and preliminary efficacy of the vitamin D analogue paricalcitol in combination with nanoliposomal irinotecan (Nal-iri) plus 5-fluorouracil/leucovorin (5-FU/LV) in patients with advanced pancreatic cancer who had progressed on gemcitabine-based therapy. Two dose levels (DL) of paricalcitol were tested: fixed dose weekly (75 mcg, DL1) and weight-based weekly (7 mcg/kg, /DL2). The primary endpoint was safety, and secondary endpoints included overall response rate, progression-free survival (PFS), and overall survival (OS). Correlative objectives aimed to identify molecular predictors of response and alterations in the tumor stroma. Results: Twenty patients (10 each in DL1 and DL2) enrolled between March 2019 and May 2021. No grade 3/4 adverse events related to paricalcitol were observed. The most common toxicities were nausea, diarrhea and fatigue, which were similar in both cohorts. Three patients discontinued study after one cycle and were not radiographically evaluable. Of the remaining 17 evaluable patients, 2 had partial response and 12 had stable disease. The median PFS for response-evaluable patients in DL1 was 4.14 months, for DL2 was 4.83 months. Intent-to-treat median OS was 6.15 and 6.66 months for DL1 and DL2, respectively. Correlative studies showed increased tumor vascularity in posttreatment samples in patients receiving the higher dose of paricalcitol (DL2). Conclusions: Paricalcitol at 7 mcg/kg/week in combination with Nal-iri/ 5-FU/LV is safely tolerated, may increase tumor vascularity and warrants further investigation.
Does increasing the number of resected lymph nodes really improve the prognosis of patients with esophageal squamous cell carcinoma?
Authors: Bo-Wei Liu, Yi-Min Gu, Long-Qi Chen
Journal: International Journal of Surgery (2023)

Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China Assistance with the study: none Financial support and sponsorship: none Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Long-Qi Chen, MD, PhD. Department of Thoracic Surgery, West China Hospital, Sichuan University. No. 37, Guo xue Alley, Chengdu 610041, China. E-mail address: [email protected] (L.-Q. Chen). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of <i>CDCP1</i> and Cardiac Fibrosis
Authors: Duan Liu, Min Wang, Vishakantha Murthy, Dennis M. McNamara, Thanh Thanh L. Nguyen, Trudy J. Philips, Hridyanshu Vyas, Huanyao Gao, Jyotan Sahni, Randall C. Starling, Leslie T. Cooper, Michelle K. Skime, Anthony Batzler, Gregory D. Jenkins, Simona Barlera, Silvana Pileggi, Luisa Mestroni, Marco Merlo, Gianfranco Sinagra, Florence Pinet, Jan Krejčí, Anna Chaloupka, Jordan D. Miller, Pascal de Groote, Daniel J. Tschumperlin, Richard M. Weinshilboum, Naveen L. Pereira
Journal: Circulation Research (2023)

Dilated cardiomyopathy (DCM) is a major cause of heart failure and carries a high mortality rate. Myocardial recovery in DCM-related heart failure patients is highly variable, with some patients having little or no response to standard drug therapy. A genome-wide association study may agnostically identify biomarkers and provide novel insight into the biology of myocardial recovery in DCM.
Considerations regarding an updated pooled analysis of minimally invasive surgery for major hepatectomy
Authors: Huayang Pang, Menghua Yan, Hao Sun
Journal: International Journal of Surgery (2023)

aGastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China bChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing, China. E-mail address: [email protected] (H. Sun). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Insights into the history and tendency of liver transplantation for liver cancer: a bibliometric-based visual analysis
Authors: Xinyu He, Shengjun Xu, Linsong Tang, Sunbin Ling, Xuyong Wei, Xiao Xu
Journal: International Journal of Surgery (2023)

Research on liver transplantation (LT) for liver cancer has gained increasing attention. This paper has comprehensively described the current status, hotspots and trends in this field. A total of 2991 relevant articles from January 1, 1963 to February 28, 2023 were obtained from the Web of Science Core Collection. VOSviewer and CiteSpace software were utilized as bibliometric tools to analyze and visualize knowledge mapping. Between 1963 and 2023, the number of papers in the area of LT for liver cancer increased continuously. A total of 70 countries/regions, 2303 institutions and 14840 researchers have published research articles, with the United States and China being the two most productive countries. Our bibliometric-based visual analysis revealed the expansion of LT indications for liver cancer and prevention/treatment of cancer recurrence as ongoing research hotspots over the past decades. Meanwhile, emerging studies also focus on downstaging/bridging treatments before LT and long-term survival of LT recipient, in particular the precise application of immunosuppressants.
Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer
Authors: Mutlay Sayan, Jiaming Huang, Wanling Xie, Ming-Hui Chen, Marian Loffredo, Elizabeth McMahon, Peter Orio, Paul Nguyen, Anthony V. D’Amico
Journal: JAMA Network Open (2023)

A shorter time interval to prostate-specific antigen (PSA) failure is associated with worse clinical outcomes; however, specific factors defining this state remain unknown.To evaluate the factors of a short time interval to PSA failure in order to identify patients for treatment escalation randomized clinical trials.This secondary analysis of a randomized clinical trial was a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial and included 350 patients with nonmetastatic unfavorable risk prostate cancer (PC).Patients were randomized 1:1 to receive androgen deprivation therapy (ADT) and radiation therapy (RT) plus docetaxel vs ADT and RT.Cumulative incidence rates curves of PSA failure, defined as PSA nadir plus 2 ng/mL or initiation of salvage therapies, and the Fine and Gray competing risks regression was used to assess the prognostic association between these factors and time to PSA failure.The study included 350 males who primarily had a good performance status (330 [94.3%] with Eastern Cooperative Oncology Group score of 0), median (range) age of 66 (43-86) years, with 167 (46.6%) having Gleason scores of 8 to 10, and 195 (55.2%) presenting with a baseline PSA of more than 10 ng/mL. After a median (IQR) follow-up of 10.2 (8.0-11.4) years, having a PSA level of 10 ng/mL to 20 ng/mL (subdistribution hazard ratio [sHR], 1.98; 95% CI, 1.28-3.07; P = .002) and a Gleason score of 8 to 10 (sHR, 2.55; 95% CI, 1.63-3.99; P < .001) were associated with a shorter time to PSA failure, and older age (sHR, 0.82; 95% CI, 0.72-0.93; P = .002) was associated with reduced risk for PSA failure after adjusting for other baseline clinical factors. The high-risk category, defined by these 3 factors, was associated with a shorter time to PSA failure (sHR, 2.69; 95% CI, 1.84-3.93; P < .001).In this secondary analysis of a randomized clinical trial of males with unfavorable risk PC, young age, PSA of 10 ng/mL or more, and a Gleason score of 8 to 10 estimated a shorter time to PSA failure. A subgroup of males at very high-risk for early PSA failure, as defined by our study, may benefit from treatment escalation with androgen receptor signaling inhibitors or cytotoxic chemotherapy and should be the subject of a prospective randomized clinical trial.NCT00116142.
Can cardiovascular reserve index (CVRI) on arrival to the trauma unit detects massive hemorrhage and predicts developing hemorrhage? observational prospective cohort study
Authors: Yossi Shaya, Michael Stein, Liron Gershovitz, Ariel Furer, Anan Khalaf, Michael J. Drescher, Uri Gabbay
Journal: International Journal of Surgery (2023)

Background: The detection of haemorrhage in trauma casualties may be delayed owing to compensatory mechanisms. This study aimed to evaluate whether the cardiovascular reserve index (CVRI) on arrival detects massive haemorrhage and predicts haemorrhage development in trauma casualties. Methods: This was an observational prospective cohort study of adult casualties (≥18 years) who were brought to a single level-1 trauma centre, enroled upon arrival and followed until discharge. Vital signs were monitored on arrival, from which the CVRI and shock index were retrospectively calculated (blinded to the caregivers). The outcome measure was the eventual haemorrhage classification group: massive haemorrhage on arrival (MHOA) (defined by massive transfusion on arrival of ≥6 [O+] packed cells units), developing haemorrhage (DH) (defined by a decrease in haemoglobin &gt;1 g/dl in consecutive tests), and no significant haemorrhage noted throughout the hospital stay. The means of each variable on arrival by haemorrhage group were evaluated using the analysis of variance. The authors evaluated the detection of MHOA in the entire population and the prediction of DH in the remainders (given that MHOA had already been detected and treated) by C-statistic predefined strong prediction by area under the curve (AUC) greater than or equal to 0.8, P less than or equal to 0.05. Results: The study included 71 patients (after exclusion): males, 82%; average age 37.7 years. The leading cause of injuries was road accident (61%). Thirty-nine (54%) patients required hospital admission; distribution by haemorrhage classification: 5 (7%) MHOA, 5 (7%) DH, and 61 (86%) no significant haemorrhage. Detection of MHOA found a strong predictive model by CVRI and most variables (AUC 0.85–1.0). The prediction of DH on arrival showed that only lactate (AUC=0.88) and CVRI (0.82) showed strong predictive model. Conclusions: CVRI showed a strong predictive model for detection of MHOA (AUC&gt;0.8) as were most other variables. CVRI also showed a strong predictive model for detection of DH (AUC=0.82), only serum lactate predicted DH (AUC=0.88), while all other variables were not found predictive. CVRI has advantages over lactate in that it is feasible in pre-hospital and mass casualty settings. Moreover, its repeatability enables detection of deteriorating trend. The authors conclude that CVRI may be a useful additional tool in the evaluation of haemorrhage.
Patterns in Physician Burnout in a Stable-Linked Cohort
Authors: Marcus V. Ortega, Michael K. Hidrue, Sara R. Lehrhoff, Dan B. Ellis, Rachel C. Sisodia, William T. Curry, Marcela G. del Carmen, Jason H. Wasfy
Journal: JAMA Network Open (2023)

Importance Physician burnout is widely reported to be an increasing problem in the US. Although prior analyses suggest physician burnout is rising nationally, these analyses have substantial limitations, including different physicians joining and leaving clinical practice. Objective To examine the prevalence of burnout among physicians in a large multispecialty group over a 5-year period. Design, Setting, and Participants This survey study was conducted in 2017, 2019, and 2021 and involved physician faculty members of the Massachusetts General Physicians Organization. Participants represented different clinical specialties and a full range of career stages. The online survey instrument had 4 domains: physician career and compensation satisfaction, physician well-being, administrative workload on physicians, and leadership and diversity. Exposure Time. Main Outcomes and Measures Physician burnout, which was assessed with the Maslach Burnout Inventory. A binary burnout measure was used, which defined burnout as a high score in 2 of the 3 burnout subscales: Exhaustion, Cynicism, and Reduced Personal Efficacy. Results A total of 1373 physicians (72.9% of the original 2017 cohort) participated in all 3 surveys. The cohort included 690 (50.3%) male, 921 (67.1%) White, and 1189 (86.6%) non-Hispanic individuals. The response rates were 93.0% in 2017, 93.0% in 2019, and 92.0% in 2021. Concerning years of experience, the cohort was relatively well distributed, with the highest number and proportion of physicians (478 [34.8%]) reporting between 11 and 20 years of experience. Within this group, burnout declined from 44.4% (610 physicians) in 2017 to 41.9% (575) in 2019 ( P = .18) before increasing to 50.4% (692) in 2021 ( P &amp;amp;lt; .001). Conclusions and Relevance Findings of this survey study suggest that the physician burnout rate in the US is increasing. This pattern represents a potential threat to the ability of the US health care system to care for patients and needs urgent solutions.
Trends in dedicated care for females with bleeding disorders within <scp>U.S.</scp> hemophilia treatment centers
Authors: Allison P. Wheeler, Ming Y. Lim, Patricia S. Huguelet, Julie Jaffray, Janice M. Staber, Kerry Funkhouser, Shannon L. Carpenter, Angela C. Weyand
Journal: American Journal of Hematology (2023)

Graphical Abstract Graphical representation of increasing percentage of female patients seen at HTCs, percentage of females by diagnosis, number of clinics in existence, and absolute number of female patients seen over a 10-year period (top left then clockwise).
Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study
Authors: Hao Fu, Jingxiong Huang, Tianzhi Zhao, Hongjian Wang, Yuhang Chen, Weizhi Xu, Yizhen Pang, Wei Guo, Long Sun, Hua Wu, Pengfei Xu, Bishan Su, Jingjing Zhang, Xiaoyuan Chen, Haojun Chen
Journal: Clinical Cancer Research (2023)

Abstract Purpose: Fibroblast activation protein (FAP) is a promising target for tumor treatment. In this study, we aimed to investigate the safety and efficacy of the albumin binder-conjugated FAP-targeted radiopharmaceutical, 177Lu-EB-FAPI (177Lu-LNC1004), in patients with metastatic radioiodine-refractory thyroid cancer (mRAIR-TC). Patients and Methods: This open-label, non-randomized, first-in-human, dose-escalation, investigator-initiated trial had a 3+3 design and involved a 6-week 177Lu-LNC1004 treatment cycle in patients with mRAIR-TC at 2.22 GBq initially, with subsequent cohorts receiving an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed. Results: 177Lu-LNC1004 administration was well tolerated, with no life-threatening adverse events observed. No patients experienced DLT in Group A (2.22 GBq/cycle). One patient experienced grade 4 thrombocytopenia in Group B (3.33 GBq/cycle); hence, another three patients were enrolled, none of whom experienced DLT. Two patients experienced grade 3 and 4 hematotoxicity in Group C (4.99 GBq/cycle). The mean whole-body effective dose was 0.17 ± 0.04 mSv/MBq. Intense 177Lu-LNC1004 uptake and prolonged tumor retention resulted in high mean absorbed tumor doses (8.50 ± 12.36 Gy/GBq). The mean effective half-lives for the whole-body and tumor lesions were 90.20 ± 7.68 and 92.46 ± 9.66 hours, respectively. According to RECIST, partial response, stable disease, and progressive disease were observed in 3 (25%), 7 (58%), and 2 (17%) patients, respectively. The objective response and disease control rates were 25% and 83%, respectively. Conclusions: FAP-targeted radioligand therapy with 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated in patients with advanced mRAIR-TC, with high radiation dose delivery to the tumor lesions, encouraging therapeutic efficacy, and acceptable side effects.
Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19
Authors: Sung Ha Lim, Hyun Jeong Ju, Ju Hee Han, Ji Hae Lee, Won-Soo Lee, Jung Min Bae, Solam Lee
Journal: JAMA Network Open (2023)

Importance Multiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified. Objective To investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19. Design, Setting, and Participants This was a retrospective population-based study conducted between October 8, 2020, and December 31, 2021, that used nationwide data from the Korea Disease Control and Prevention Agency COVID-19 National Health Insurance Service cohort and included individuals who received a diagnosis of COVID-19 via polymerase chain reaction testing and a control group with no evidence of COVID-19 identified from National Health Insurance Service of Korea cohort. Data analysis was conducted from September 2022 to August 2023. Exposures Receipt of diagnosis of COVID-19. Main Outcomes and Measures The primary outcomes were the incidence and risk of autoimmune and autoinflammatory connective tissue disorders following COVID-19. A total of 32 covariates, including demographics, socioeconomic statuses, lifestyle factors, and comorbidity profiles, were balanced through inverse probability weighting. The incidences and risks of autoimmune and autoinflammatory connective tissue disorders were compared between the groups using multivariable Cox proportional hazard analyses. Results A total of 354 527 individuals with COVID-19 (mean [SD] age, 52.24 [15.55] years; 179 041 women [50.50%]) and 6 134 940 controls (mean [SD] age, 52.05 [15.63] years; 3 074 573 women [50.12%]) were included. The risks of alopecia areata (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.05-1.19), alopecia totalis (aHR, 1.74; 95% CI, 1.39-2.17), antineutrophil cytoplasmic antibody–associated vasculitis (aHR, 2.76; 95% CI, 1.64-4.65), Crohn disease (aHR, 1.68; 95% CI, 1.31-2.15), and sarcoidosis (aHR, 1.59; 95% CI, 1.00-2.52) were higher in the COVID-19 group. The risks of alopecia totalis, psoriasis, vitiligo, vasculitis, Crohn disease, ulcerative colitis, rheumatoid arthritis, adult-onset Still disease, Sjögren syndrome, ankylosing spondylitis, and sarcoidosis were associated with the severity of COVID-19. Conclusions and Relevance In this retrospective cohort study, COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders, indicating that long-term management of patients with COVID-19 should include evaluation for such disorders.
Adverse effects of <scp>delta‐9‐tetrahydrocannabinol</scp> on sickle red blood cells
Authors: Aline Hatem, Sofia Esperti, Nicoletta Murciano, Min Qiao, Maria Giustina Rotordam, Nadine Becker, Elie Nader, Felix Maurer, Laurent Pérès, Guillaume Bouyer, Lars Kaestner, Philippe Connes, Stéphane Egée
Journal: American Journal of Hematology (2023)

THC triggers a pronounced entry of Ca2+ , which may be deleterious, into sickle cell red blood cells via activation of the TRPV2 channel.
An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better?
Authors: Dong Wu, Jun Lu, Jia Lin, Bin-bin Xu, Zhen Xue, Hua-Long Zheng, Guo-sheng Lin, Jiao-bao Huang, Li-li Shen, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Yu-Bin Ma, Mark J. Truty, Chang-Ming Huang
Journal: International Journal of Surgery (2023)

Due to lacking evidence on surveillance for gastric cancer (GC), this study aimed to determine the optimal postsurgical surveillance strategy for pathological stage (pStage) II/III GC patients and compare its cost-effectiveness with traditional surveillance strategies.
A commentary on ‘The impact of diabetes on postoperative outcomes following spine surgery: a meta-analysis of 40 cohort studies with 2.9 million participants’
Authors: Sung Huang Laurent Tsai
Journal: International Journal of Surgery (2023)

Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, and School of Medicine Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, and School of Medicine, Chang Gung University, Taoyuan 333, Taiwan. E-mail address: [email protected] (S. H. L. Tsai). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/